Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Exploratory Study to Identify Radiomics Classifiers for Lung Cancer Histology.

Wu W, Parmar C, Grossmann P, Quackenbush J, Lambin P, Bussink J, Mak R, Aerts HJ.

Front Oncol. 2016 Mar 30;6:71. doi: 10.3389/fonc.2016.00071. eCollection 2016.

2.

Myoferlin expression in non-small cell lung cancer: Prognostic role and correlation with VEGFR-2 expression.

Song DH, Ko GH, Lee JH, Lee JS, Lee GW, Kim HC, Yang JW, Heo RW, Roh GS, Han SY, Kim DC.

Oncol Lett. 2016 Feb;11(2):998-1006. Epub 2015 Dec 2.

3.

A Pilot Proteogenomic Study with Data Integration Identifies MCT1 and GLUT1 as Prognostic Markers in Lung Adenocarcinoma.

Stewart PA, Parapatics K, Welsh EA, Müller AC, Cao H, Fang B, Koomen JM, Eschrich SA, Bennett KL, Haura EB.

PLoS One. 2015 Nov 5;10(11):e0142162. doi: 10.1371/journal.pone.0142162. eCollection 2015.

4.
5.

Cross-cancer profiling of molecular alterations within the human autophagy interaction network.

Lebovitz CB, Robertson AG, Goya R, Jones SJ, Morin RD, Marra MA, Gorski SM.

Autophagy. 2015;11(9):1668-87. doi: 10.1080/15548627.2015.1067362.

6.

NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy.

Xu C, Buczkowski KA, Zhang Y, Asahina H, Beauchamp EM, Terai H, Li YY, Meyerson M, Wong KK, Hammerman PS.

Mol Cancer Ther. 2015 Oct;14(10):2382-9. doi: 10.1158/1535-7163.MCT-15-0077. Epub 2015 Jul 23.

PMID:
26206333
7.

Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations.

Sholl LM, Nishino M, Pokharel S, Mino-Kenudson M, French CA, Janne PA, Lathan C.

J Thorac Oncol. 2015 Jun;10(6):951-9. doi: 10.1097/JTO.0000000000000545.

8.

Utility of five commonly used immunohistochemical markers TTF-1, Napsin A, CK7, CK5/6 and P63 in primary and metastatic adenocarcinoma and squamous cell carcinoma of the lung: a retrospective study of 246 fine needle aspiration cases.

Gurda GT, Zhang L, Wang Y, Chen L, Geddes S, Cho WC, Askin F, Gabrielson E, Li QK.

Clin Transl Med. 2015 Apr 21;4:16. doi: 10.1186/s40169-015-0057-2. eCollection 2015.

9.

LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-small Cell Lung Cancer Plasticity and Therapeutic Response.

Li F, Han X, Li F, Wang R, Wang H, Gao Y, Wang X, Fang Z, Zhang W, Yao S, Tong X, Wang Y, Feng Y, Sun Y, Li Y, Wong KK, Zhai Q, Chen H, Ji H.

Cancer Cell. 2015 May 11;27(5):698-711. doi: 10.1016/j.ccell.2015.04.001. Epub 2015 Apr 30.

10.

Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases.

Paik PK, Shen R, Won H, Rekhtman N, Wang L, Sima CS, Arora A, Seshan V, Ladanyi M, Berger MF, Kris MG.

Cancer Discov. 2015 Jun;5(6):610-21. doi: 10.1158/2159-8290.CD-14-1129. Epub 2015 Apr 30.

11.

Epidermal growth factor receptor gene mutation status in pure squamous-cell lung cancer in Chinese patients.

Zhang Q, Zhu L, Zhang J.

BMC Cancer. 2015 Mar 1;15:88. doi: 10.1186/s12885-015-1056-9.

12.

Reevaluation and reclassification of resected lung carcinomas originally diagnosed as squamous cell carcinoma using immunohistochemical analysis.

Kadota K, Nitadori J, Rekhtman N, Jones DR, Adusumilli PS, Travis WD.

Am J Surg Pathol. 2015 Sep;39(9):1170-80. doi: 10.1097/PAS.0000000000000439.

PMID:
25871623
13.

Robust meta-analysis of gene expression using the elastic net.

Hughey JJ, Butte AJ.

Nucleic Acids Res. 2015 Jul 13;43(12):e79. doi: 10.1093/nar/gkv229. Epub 2015 Mar 31.

14.

Advances in lung adenocarcinoma classification: a summary of the new international multidisciplinary classification system (IASLC/ATS/ERS).

Tang ER, Schreiner AM, Pua BB.

J Thorac Dis. 2014 Oct;6(Suppl 5):S489-501. doi: 10.3978/j.issn.2072-1439.2014.09.12. Review.

15.

Hidden treasures in "ancient" microarrays: gene-expression portrays biology and potential resistance pathways of major lung cancer subtypes and normal tissue.

Kerkentzes K, Lagani V, Tsamardinos I, Vyberg M, Røe OD.

Front Oncol. 2014 Sep 29;4:251. doi: 10.3389/fonc.2014.00251. eCollection 2014.

16.

PD-1 gene promoter polymorphisms correlate with a poor prognosis in non-small cell lung cancer.

Sasaki H, Tatemaysu T, Okuda K, Moriyama S, Yano M, Fujii Y.

Mol Clin Oncol. 2014 Nov;2(6):1035-1042. Epub 2014 Jul 24.

17.

Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist's Perspective.

Brega E, Brandao G.

Front Oncol. 2014 Jul 16;4:182. doi: 10.3389/fonc.2014.00182. eCollection 2014. Review.

18.

Expression and diagnostic values of calretinin and CK5/6 in cholangiocarcinoma.

Zhang L, Frank R, Furth EE, Ziober AF, LiVolsi VA, Zhang PJ.

Exp Hematol Oncol. 2014 Apr 23;3:12. doi: 10.1186/2162-3619-3-12. eCollection 2014.

19.

Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy.

Stinchcombe TE.

Med Oncol. 2014 May;31(5):960. doi: 10.1007/s12032-014-0960-1. Epub 2014 Apr 19. Review.

20.

The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non-small cell lung cancer.

Ao MH, Zhang H, Sakowski L, Sharma R, Illei PB, Gabrielson E, Askin F, Li QK.

Hum Pathol. 2014 May;45(5):926-34. doi: 10.1016/j.humpath.2014.01.005. Epub 2014 Jan 25.

Items per page

Supplemental Content

Write to the Help Desk